Fundraising Fox
/Companies
Sign in

CatenaBio

YC S21

Berkeley, US · Founded 2020 · 7 employees · 15 known investors

Find your way into CatenaBio

10,406 people in our graph share verified history with the CatenaBio team — schools, employers, funds. One of them is your warm intro.

David Coltonunlockedknows Marco Lobba · together at YC S21 (overlapped)
×4knows the team · via YC S21
knows the team · via Pomona College
×6knows the team · via UC Berkeley

CatenaBio develops precision conjugation technology using native amino acids to enable biotherapeutic fusions of small molecules, nucleic acids, enzymes, and cells. The company partners with pharmaceutical firms to advance development of novel therapeutic modalities.

BiotechDeep TechHealthtechMedical DevicesTherapeutics

Founders & leadership· Y Combinator alumni (S21)

CatenaBio was founded in 2020 by Marco Lobba, Matthew Francis, and Marco Lobba, Ph.D..

MLMarco Lobba
Marco LobbaCo-Founder/CEOMarco Lobba is CEO and co-founder of Catena Biosciences. He holds a Ph.D. from UC Berkeley, where his doctoral research spanned the labs of Matt Francis and Jennifer Doudna.
MF
Matthew FrancisFounderFounder at Catena Biosciences
MLMarco Lobba, Ph.D.
Marco Lobba, Ph.D.Co-Founder/CEOMarco Lobba completed a Ph.D. under Matt Francis and Jennifer Doudna, where he conducted research that led to the founding of CatenaBio, which develops precision conjugation technology for biotherapeutic applications.

Investors · 15

Civilization Ventures Management, Llclisted by Civilization Ventures Management, LlcTiburon · $1M – $10M

How we know: Civilization Ventures Management, Llc's portfolio page · bakarlabs.berkeley.edu · funding news · the VCSheet dataset · Not right? Tell us

Creative Destruction Lab (CDL)listed by Creative Destruction Lab (CDL)Toronto · $50K – $250K
FREEFLOWlisted by FREEFLOWBerkeley

How we know: the VCSheet dataset · Not right? Tell us

Iaso Ventureslisted by Iaso VenturesCambridge

How we know: a partner's Signal profile · Not right? Tell us

LongeVClisted by LongeVCWashington D.C.

How we know: LongeVC's portfolio page · funding news · bakarlabs.berkeley.edu · Not right? Tell us

MBX Capitallisted by MBX CapitalClaymont · $250K – $2.5M

How we know: MBX Capital's portfolio page · the VCSheet dataset · Not right? Tell us

Y Combinatorlisted by Y CombinatorSan Francisco · $500K

How we know: the Y Combinator directory · Not right? Tell us

Axial VCreportedSan Francisco · $100K – $5M

How we know: the VCSheet dataset · Not right? Tell us

Caffeinated CapitalreportedSan Francisco · $3M – $50M

How we know: bakarlabs.berkeley.edu · Not right? Tell us

NYBC VenturesreportedNew York

How we know: the VCSheet dataset · Not right? Tell us

Social Impact CapitalreportedNew York · $100K – $1.5M

How we know: the VCSheet dataset · Not right? Tell us

Also in the syndicate · 3

BrightEdge - American Cancer SocietyCalifornia Innovation FundFreeflow Ventures

Funding

SEC filings, press & company announcements

Source: company announcements and press reports — follow each round's link for the claim.

Frequently asked questions

What does CatenaBio do?
CatenaBio develops precision conjugation technology using native amino acids to enable biotherapeutic fusions of small molecules, nucleic acids, enzymes, and cells. The company partners with pharmaceutical firms to advance development of novel therapeutic modalities.
Who founded CatenaBio?
CatenaBio was founded by Marco Lobba, Matthew Francis, Marco Lobba, Ph.D. in 2020.
Who are CatenaBio's investors?
CatenaBio's investors include CALIFORNIA INNOVATION, Civilization Ventures Management, Llc, Creative Destruction Lab (CDL), FREEFLOW, Iaso Ventures, LongeVC, MBX Capital, Y Combinator and 4 more.
Where is CatenaBio headquartered?
CatenaBio is headquartered in Berkeley, US.